Gastroenterologia y hepatologia最新文献

{"title":"Hepatic abscess secondary to gastrohepatic migration of a fishbone.","authors":"Alex Gil-Ordóñez, Gerard Rafart-Martínez, Carles Pérez-Serrano, Carolina González-Abós, Sergio Jiménez-Serrano","doi":"10.1016/j.gastrohep.2025.502435","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502435","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502435"},"PeriodicalIF":2.2,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Trends in Colectomy Rates for Ulcerative Colitis in Brazil: An Analysis of the Unified Public Healthcare System.","authors":"Mariane Christina Savio, Julia Ceconello Coelho, Emilia Oliveira, Daniela Oliveira Magro, Douglas Andreas Valverde, Abel Botelho Quaresma, Rafaela de Araujo Molteni, Maria Paz Gimenez Villamil, Paulo Gustavo Kotze","doi":"10.1016/j.gastrohep.2025.502434","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502434","url":null,"abstract":"<p><strong>Introduction: </strong>Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant global prevalence. Despite advancements in medical management, including the widespread use of biologic agents and small molecules, approximately 15-20% of patients eventually require surgery. This study aimed to analyze colectomy and hospitalization rates for UC in Brazil from 2012 to 2022 and assess their temporal trends.</p><p><strong>Methods: </strong>This was a retrospective, observational, population-based study using public database records from January 1, 2012, to December 31, 2022. The study included all patients with one or more diagnostic codes associated with UC (ICD-10) who underwent a UC-related surgical procedure during the study period.</p><p><strong>Results: </strong>A total of 178,552 unique UC patients were identified. UC prevalence increased significantly, from 17.31 per 100,000 in 2012 to 84.23 per 100,000 in 2022, with an annual average percentage change (AAPC) of 15% (95% CI 14.97-15.11, p < 0.001). The Southeastern and Southern regions accounted for the highest number of cases. Among the 1,374 surgical procedures identified, 69.4% were total colectomies, and 10.6% were pouch procedures. By the end of 2022, the proportion of surgeries relative to the total number of UC patients was 0.7%, with a declining trend (AAPC -11.8%; 95% CI -13.38 to -10.33, p < 0.001). Hospitalization rates also showed a significant decline over time (AAPC -14.3%; 95% CI -14.75 to -14.03, p < 0.001).</p><p><strong>Conclusions: </strong>UC prevalence in Brazil has increased substantially over the past decade. However, colectomy rates remain low and have shown a declining trend over the same period. Additionally, there has been a notable reduction in hospitalization rates, reflecting potential improvements in UC management and disease control.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502434"},"PeriodicalIF":2.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and microbiological profile in obstructive biliary disease in a tertiary center: observational study.","authors":"Marusia González-Villarreal, Joel Omar Jáquez-Quintana, Paola Bocanegra-Ibarias, Juan Manuel Millán-Alanís, Ariadnee Irma Reyna-Aréchiga, Víctor Andrés Cab-Morales, Valeria Hernández-Rodarte, Adrián Camacho-Ortiz, Héctor Jesús Maldonado-Garza","doi":"10.1016/j.gastrohep.2025.502431","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502431","url":null,"abstract":"<p><strong>Aims: </strong>There is limited information on bacterial isolation, antibiotic susceptibility, and microbiological profile in obstructive biliary disease (OBD). Providing information on this could help offer more effective empirical antibiotic therapy in clinical cholangitis. This study aims to evaluate the clinical and microbiological profile in obstructive biliary disease.</p><p><strong>Patients and methods: </strong>The study was conducted at a tertiary academic center between August 2021 and January 2023. Hospitalized patients with OBD, with indication for biliary drainage by endoscopic retrograde cholangiopancreatography, were recruited. Biliary samples were obtained following a standardized protocol, and were processed in laboratory for Gram staining, culture, subculture. Microorganisms were identified and subjected to antibiotic susceptibility testing.</p><p><strong>Results: </strong>A total of 61 patients were included, 73.8% were women, average age was 44.8 years. Overweight/obesity was the most common comorbidity (62.3%); clinical cholangitis was present in 75.4%. Biliary lithiasis was the most common etiology of OBD (86.9%). Positive cultures were obtained in 44.3% of participants, predominating the group of Gram-positive bacteria; individually, E. coli was the most isolated microorganism. A 68.2% of bacteria showed resistance to at least one antibiotic. We found significant associations between bile appearance and cholangitis, bile appearance and OBD etiology, OBD etiology and cholangitis severity. Male sex, increased age, tobacco use were associated with positive cultures. We found a spectrum of microorganisms and antibiotic susceptibilities partially different from those of Tokyo Guidelines 2018 and other publications.</p><p><strong>Conclusions: </strong>Our findings highlight the need to characterize microbiological profile in OBD according to each region.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502431"},"PeriodicalIF":2.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Food to Alcohol: Why Some Patients Develop New Addictions After Bariatric Surgery\".","authors":"Edilmar Alvarado-Tapias, Ramon Bataller, David Martí-Aguado","doi":"10.1016/j.gastrohep.2025.502430","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502430","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502430"},"PeriodicalIF":2.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eficacia y seguridad de la terapia biológica en el tratamiento de la enfermedad de Crohn: una revisión exhaustiva de metanálisis y revisiones sistemáticas.","authors":"Ping Jiang, Yunchen Li, Jidong Tian, Yuan Luo, Hu Xiangxiang, Xinhui Qiu, Chen Guo, Fu Cuicui","doi":"10.1016/j.gastrohep.2025.502432","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502432","url":null,"abstract":"<p><strong>Objective: </strong>To present an overview to summarize the efficacy and safety of biologics for the treatment of Crohn's disease (CD).</p><p><strong>Methods: </strong>We gathered systematic reviews or meta-analyses on the efficacy and safety of biologic therapy for CD from the beginning to September 30, 2023, by searching the databases of the Chinese National Knowledge Infrastructure (CNKI), WanFang Data, China Science and Technology Journal Database, Web of Science, the Cochrane Library, PubMed, and Embase. Analysing reviews and extracting data, two researchers worked independently. Any discrepancies in the two researchers' assessments of the review process were reevaluated, and the argument was settled by consulting to other researchers. The following details was taken out of the data: author, publication year, study type, number of included studies, country of study, sample size, risk bias tools, biologic therapy, and primary outcomes. Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) and the AMSTAR-2, a critical appraisal tool for systematic reviews (2nd edition), were then utilized to assess the methodological quality and reporting quality of the evidence.</p><p><strong>Results: </strong>There were 19 reviews in all. 1 systematic review, 5 meta-analyses, and 13 systematic reviews and meta-analyses were among the reviews that were included. 9 studies met the high quality, 5 met the moderate quality, 3 met the poor quality, and 2 met the critically low quality requirements of the AMSTAR-2 criteria.</p><p><strong>Conclusions: </strong>The analysis of the evidence finds biologic agents for CD are effective and safe. Overall, there was moderate to high quality biologic evidence for CD, but future head-to-head controlled studies are required to better inform the relative positioning of these drugs for the management of CD.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502432"},"PeriodicalIF":2.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncommon Etiologies of Mesenteric Ischemia: Beyond Atherosclerosis.","authors":"Ana Lancho Muñoz, José María López Tobaruela, Estefanía Domínguez Banegas, Eduardo Redondo Cerezo","doi":"10.1016/j.gastrohep.2025.502402","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2025.502402","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502402"},"PeriodicalIF":2.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study.","authors":"Sandro da Costa Ferreira, Rogério Serafim Parra, Ligia Yukie Sassaki, José Miguel Luz Parente, Munique Kurtz de Mello, Liliana Andrade Chebli, Rafael Luís Luporini, Antonio José Tiburcio Alves Junior, Fernando Jorge Firmino Nóbrega, Bruno César da Silva, Eron Fábio Miranda, Abel Botelho Quaresma, Guilherme Mattioli Nicollelli, Rodrigo Galhardi Gasparini, Renata de Medeiros Dutra, Juarez Roberto de Oliveira Vasconcelos, Katia da Conceição da Silva, Daniéla Oliveira Magro, Marcello Rabello Imbrizi, Cristiane Kibune Nagasako, Omar Féres, Luiz Ernesto de Almeida Troncon, Paulo Gustavo Kotze, Júlio Maria Fonseca Chebli","doi":"10.1016/j.gastrohep.2025.502396","DOIUrl":"10.1016/j.gastrohep.2025.502396","url":null,"abstract":"<p><strong>Objective: </strong>Vedolizumab (VDZ) and infliximab (IFX) are first-line therapies for moderate-to-severe ulcerative colitis (UC). Despite their widespread use, there are no direct comparative studies, and real-world data, particularly in Latin America, are limited. This study compared the effectiveness and safety of VDZ and IFX in biologic-naïve UC patients.</p><p><strong>Methods: </strong>This retrospective cohort study included patients with moderate-to-severe UC (Mayo score 6-12, endoscopic sub-score ≥2) treated with VDZ or IFX. Primary endpoints were clinical remission (partial Mayo score ≤2), endoscopic remission (Mayo sub-score=0), and steroid-free clinical remission at week 52. Secondary endpoints included clinical response, endoscopic response, biological therapy optimization, adverse events (AEs), hospitalizations, and biochemical remission at week 52. Propensity score adjustment (1/PS) was used to adjust for potential confounders.</p><p><strong>Results: </strong>A total of 297 UC patients (156 IFX, 141 VDZ) were analyzed. Clinical remission at week 52 was 82.3% for VDZ and 77.6% for IFX (p=0.11), while endoscopic remission was higher in VDZ patients (47.4% vs. 33.1%, p=0.03). Steroid-free clinical remission rates were similar between groups (p=0.98). Endoscopic response at week 52 favored VDZ (78.4% vs. 62.7%, p<0.001), and VDZ had higher treatment persistence (80.8% vs. 61.8%, p<0.001). AEs and hospitalizations were more frequent in IFX patients (p<0.001).</p><p><strong>Conclusions: </strong>Both VDZ and IFX are effective in biologic-naïve UC patients, however VDZ demonstrated superior endoscopic outcomes, higher treatment persistence, and a better safety profile, supporting its use as a first-line therapy.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502396"},"PeriodicalIF":2.2,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of mobile applications in the management of hepatitis B: A systematic review.","authors":"Judit Romero-Vico, Elena Vargas-Accarino, Adriana Palom, Núria Fabrellas, Maria Buti","doi":"10.1016/j.gastrohep.2025.502395","DOIUrl":"10.1016/j.gastrohep.2025.502395","url":null,"abstract":"<p><p>Hepatitis B virus is a public health issue, with severe complications such as cirrhosis and liver cancer that impose significant economic, emotional, and psychosocial burdens. Despite the availability of a vaccine and oral treatments, effective management of this disease remains a challenge. Telemedicine and mobile applications have the potential to improve the management of chronic diseases; this study examines their utility in hepatitis B. A search was conducted in four databases in November 2024 following the PRISMA guidelines. Out of 216 articles, seven studies were included. These studies evaluated the use of mobile applications in providing access to information, detection and linkage to care, quality of life assessment, and vaccination promotion. The findings showed the usefulness of these tools, considering mobile applications as a helpful tool in the management and prevention of hepatitis B.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502395"},"PeriodicalIF":2.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study.","authors":"Laura Andrés, Marisa Iborra, Raquel Vicente, Lara Arias, Pilar Nos, Ana Royo-Esteban, Beatriz Sicilia","doi":"10.1016/j.gastrohep.2025.502379","DOIUrl":"10.1016/j.gastrohep.2025.502379","url":null,"abstract":"<p><strong>Introduction: </strong>Subcutaneous (sc) vedolizumab is an alternative to intravenous (iv) vedolizumab for the treatment of patients with mild-to-moderate flares of inflammatory bowel disease (IBD).</p><p><strong>Aims: </strong>To analyse the persistence rate of the sc vedolizumab and its pharmacokinetics in patients previously treated with iv vedolizumab; describing clinical and biochemical remission rates at one year, and comparing previous intravenous intensification regimens.</p><p><strong>Methods: </strong>Multicenter, descriptive, observational, and retrospective study of a cohort of 54 patients with IBD treated with iv vedolizumab for more than six months, who were switched to sc vedolizumab under a standard regimen, 32 patients (59%) with a diagnosis of ulcerative colitis (UC) and 22 patients (41%) with Crohn's disease (CD) RESULTS: After one year of follow-up, 93% of the patients continued with vedolizumab, 100% were in clinical remission, and 86% achieved biochemical remission (calprotectin <150). A progressive increase in vedolizumab levels was observed after switching to sc vedolizumab, with statistical significance (p<0.05). 14 patients (25.9%) were on an intensified regimen before switching to sc vedolizumab; however, all patients remained on subcutaneous vedolizumab at a dose of 108 mg every two weeks without the need for intensification.</p><p><strong>Conclusion: </strong>After switching to sc vedolizumab in patients with endovenous vedolizumab treatment, high persistence rate at one year of follow-up is achieved, with a greater tendency to biochemical remission, which is more pronounced in previously intensified patients without the need for subcutaneous vedolizumab intensification.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502379"},"PeriodicalIF":2.2,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysplasia screening in inflammatory bowel disease patients: to whom, when and how.","authors":"María Pilar Ballester, Cristina Rubín de Célix, Lucía Madero, Margalida Calafat, Iria Baston-Rey, Eduard Brunet-Mas","doi":"10.1016/j.gastrohep.2025.502373","DOIUrl":"10.1016/j.gastrohep.2025.502373","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502373"},"PeriodicalIF":2.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}